结直肠癌发生的分子病理学基础

国际肿瘤学杂志››2014,Vol. 41››Issue (5): 353-357.doi:10.3760/cma.j.issn.1673-422X.2014.05.011

结直肠癌发生的分子病理学基础

蒋伟国,黄尤光

660101西双版纳农垦医院普外科（蒋伟国）；650106 昆明医科大学第三附属医院肿瘤研究所(蒋伟国、黄尤光)

收稿日期:2013-11-22修回日期:2013-12-25出版日期:2014-05-08发布日期:2014-04-28
通讯作者:黄尤光 E-mail:huangyouguang2008@126.com
基金资助:

云南省应用基础研究计划（2011FZ108）；云南省卫生科技计划（2012WS0040）

Basis of molecular pathology in colorectal carcinogenesis

Jiang Weiguo, Huang Youguang

Department of General Surgery, Land Reclamation Hospital of Xishuangbanna, Xishuangbanna 650101; Cancer Research Institute, Third Affiliated Hospital of Kunming Medical University, Kunming 650106, China

Received:2013-11-22Revised:2013-12-25Online:2014-05-08Published:2014-04-28
Contact:Huang Youguang E-mail:huangyouguang2008@126.com

摘要/Abstract

摘要：结直肠癌发生是遗传学和表观遗传学改变累积的结果。基因组不稳定导致基因突变和DNA甲基化模式改变是结直肠癌发生的主要分子事件。鉴定不同患者中导致结直肠癌发生的关键基因突变及甲基化表型，对结直肠癌进行分子病理分型和诊断，是进行个体化治疗和靶向治疗的前提。

蒋伟国,黄尤光. 结直肠癌发生的分子病理学基础[J]. 国际肿瘤学杂志, 2014, 41(5): 353-357.

Jiang Weiguo, Huang Youguang. Basis of molecular pathology in colorectal carcinogenesis[J]. Journal of International Oncology, 2014, 41(5): 353-357.

［1］李祯, 生秀杰. 结肠癌转移相关基因1与肿瘤［J］. 国际肿瘤学杂志, 2013, 40(1):15-18. ［2］ Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage Ⅱ and Ⅲ colon cancer: an assessment of their prognostic and oxaliplatin predictive value［J］. Clin Cancer Res, 2012, 18(23):6531-6541. ［3］ Lagarde P, Pérot G, Kauffmann A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors［J］. Clin Cancer Res, 2012, 18(3):826-838. ［4］ Shull AY, Clendenning ML, GhoshalGupta S, et al. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients［J］. PLoS One, 2013, 8(3):e58731. ［5］ Pagin A, Zerimech F, Leclerc J, et al. Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repairdeficient tumours［J］. Br J Cancer, 2013, 108(10):2079-2087. ［6］ Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications［J］. Clin Cancer Res, 2012, 18(6):1506-1512. ［7］ Pinheiro M, Ahlquist T, Danielsen SA, et al. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin［J］. BMC Cancer, 2010, 10:587-596. ［8］ Chen W, Yuan L, Cai Y, et al. Identification of chromosomal copy number variations and novel candidate loci in hereditary nonpolyposis colorectal cancer with mismatch repair proficiency［J］. Genomics, 2013, 102(1):27-34. ［9］ Fournier A, Sasai N, Nakao M, et al. The role of methylbinding proteins in chromatin organization and epigenome maintenance［J］. Brief Funct Genomics, 2012, 11(3):251-264. ［10］ Walton EL, Francastel C, Velasco G. Maintenance of DNA methylation: Dnmt3b joins the dance［J］. Epigenetics, 2011, 6(11):1373-1377. ［11］ Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location［J］. Br J Cancer, 2013, 109(4):1004-1012. ［12］ Bae JM, Kim JH, Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype［J］. Histol Histopathol, 2013, 28(5):585-595. ［13］ Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer［J］. N Engl J Med, 2009, 361(25):2449-2460. ［14］ Gay LJ, Mitrou PN, Keen J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPICNorfolk study［J］. J Pathol, 2012, 228(3):405-415. ［15］ Zhang T, Fields JZ, Opdenaker L, et al. Survivininduced AuroraB kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development［J］. Am J Pathol, 2010, 177(6):2816-2826. ［16］ Lau T, Chan E, Callow M, et al. A novel tankyrase smallmolecule inhibitor suppresses APC mutationdriven colorectal tumor growth［J］. Cancer Res, 2013, 73(10):3132-3144. ［17］侯庆生, 丁渭, 陈德喜. p53凋亡刺激蛋白2对饥饿诱导的大肠癌HCT116p53+/+细胞凋亡、周期和自噬的影响［J］. 国际肿瘤学杂志, 2013, 40(4):298-302. ［18］ Yang W, Rozan LM, McDonald ER, et al. CARPs are ubiquitin ligases that promote MDM2independent p53 and phosphop53ser20 degradation［J］. J Biol Chem, 2007, 282(5):3273-3281. ［19］ Muller PA, Vousden KH. p53 mutations in cancer［J］. Nat Cell Biol, 2013, 15(1):2-8. ［20］ Pineda M, González S, Lázaro C, et al. Detection of genetic alterations in hereditary colorectal cancer screening［J］. Mutat Res, 2010, 693(1-2):19-31. ［21］ Bellam N, Pasche B. Tgfbeta signaling alterations and colon cancer［J］. Cancer Treat Res, 2010, 155:85-103. ［22］ Lee J, Ballikaya S, Schnig K, et al. Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116［J］. PLoS One, 2013, 8(2):e57074. ［23］ Shima K, Morikawa T, Yamauchi M, et al. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers［J］. PLoS One, 2011, 6(9):e25062. ［24］ Fleming NI, Jorissen RN, Mouradov D, et al. Eppert K, SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer［J］. Cancer Res, 2013, 73(2):725-735. ［25］ Stankic M, Pavlovic S, Chin Y, et al. TGFβId1 signaling opposes twist1 and promotes metastatic colonization via a mesenchymaltoepithelial transition［J］. Cell Rep, 2013, 5(5):12281242. ［26］ Berlin J. Beyond exon 2—the developing story of RAS mutations in colorectal cancer［J］. N Engl J Med, 2013, 369(11):1059-1060. ［27］ Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial［J］. J Natl Cancer Inst, 2013, 105(23):1789-1798. ［28］ Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents［J］. Clin Cancer Res, 2013, 19(3):657-667. PMID: 23251002 ［29］ Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer［J］. Clin Cancer Res, 2012, 18(21):5856-5864.

[1]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	刘德宝, 孙子雯, 鲁守堂, 徐海东.ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[7]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇.Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[8]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣.三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[9]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[10]	刘博翰, 黄俊星.溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[11]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺.结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[12]	徐良富, 李袁飞.MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[13]	刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[14]	邓莉莉, 段星宇, 李保中.HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦.伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.